Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Dapivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 01 Apr 2022 Results published in the AIDS Research and Human Retroviruses
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.
- 30 Jul 2018 Status changed from recruiting to active, no longer recruiting.